Insulet Corporation (PODD) 32.11 $PODD
Health insurer's limit on insulin pumps worries patients
By TOM MURPHY - AP - Fri Jun 24, 10:18AM CDT
Stephanie Rodenberg-Lewis wasn't happy with her insulin pump and finally switched two years ago to another brand. Now her health insurer is pushing her to go back.
PODD: 32.11 (+0.97), UNH: 141.27 (+0.47), AET: 117.00 (+1.53)
What Investors are Making of These Healthcare Stocks? - Antares Pharma, Globus Medical, NuVasive, and Insulet
PR Newswire - Fri Jun 24, 6:49AM CDT
Since the financial crisis, the Healthcare sector has proven to be defensive against market downturns, continuing to present opportunities for growth. Today's featured companies on Stock-Callers.com belong in this arena: Antares Pharma Inc. (NASDAQ: ATRS), Globus Medical Inc. (NYSE: GMED), NuVasive Inc. (NASDAQ: NUVA), and Insulet Corp. (NASDAQ: PODD). Learn more about these stocks and receive your complimentary trade alerts at:
PODD: 32.11 (+0.97), GMED: 24.87 (+0.42), NUVA: 60.82 (+1.11), ATRS: 1.03 (+0.02)
First Week of PODD August 19th Options Trading
DividendChannel.com - Tue Jun 21, 9:49AM CDT
Investors in Insulet Corp saw new options begin trading this week, for the August 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PODD options chain for the new August 19th contracts and identified one...
PODD: 32.11 (+0.97)
Insulet Partners with Joslin Diabetes Center to Implement a Unique Training Certification for Insulet's Clinical Team
BusinessWire - Fri Jun 10, 5:00AM CDT
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod(R) Insulin Management System, today announced that almost 100 members of Insulet's North American clinical team have completed a customized certification program designed and led by the Joslin Diabetes Center for Insulet. The Advanced Diabetes Educator in Pump Therapy (ADEPT(TM)) certification provides Insulet's clinical team with customized, advanced training to deliver enhanced support for individuals who are managing their diabetes using continuous subcutaneous insulin infusion therapy. The Company's partnership with Joslin will enable Insulet's clinical team to provide unparalleled training and support for healthcare practitioners and their Omnipod patients.
PODD: 32.11 (+0.97)
Insulet to Present Omnipod(R) Clinical Studies on Type 1 and Type 2 Diabetes During the American Diabetes Association's 76th Scientific Sessions
BusinessWire - Wed Jun 08, 5:38PM CDT
--Dr. Frank Doyle to Share Exciting New Data on the Insulet-Licensed Artificial Pancreas Algorithm
PODD: 32.11 (+0.97)
Insulet Rises 2.31% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon May 23, 4:28PM CDT
Insulet (NASDAQ
ODD) traded in a range yesterday that spanned from a low of $28.33 to a high of $29.42. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $28.86 on volume of 332,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PODD: 32.11 (+0.97)
Insulet Launches New Omnipod(R) Podder(TM) Community Platform
BusinessWire - Mon May 23, 5:00AM CDT
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod(R) Insulin Management System (Omnipod System), today announced the launch of a new online user community platform. This new platform will increase patient engagement and awareness of Omnipod by empowering Omnipod customers to share their experiences and insights and provide support to the large and growing Podder(TM) community. The launch of the Podders community platform coincides with Insulet's exciting new patient mobile app and branding, as well as the Company's debut on social media via Facebook (myomnipod) and Twitter (@myomnipod).
PODD: 32.11 (+0.97)
Why Insulet Corporation and Tandem Diabetes Care Both Tanked Today
Brian Feroldi, The Motley Fool - Motley Fool - Tue May 03, 3:50PM CDT
PHOTO CREDIT: INSULET. What: Shares of Insulet Corporation and Tandem Diabetes Care , both medical-device companies primarily focused on creating products that help treat diabetes, plunged by double digits today after Tandem released some...
PODD: 32.11 (+0.97), TNDM: 7.71 (+0.26)
Insulet Pumps Out 69% Revenue Growth in Q1, Reaffirms 2016 Guidance
Beth McKenna, The Motley Fool - Motley Fool - Tue May 03, 2:04PM CDT
Insulet reported its first-quarter 2016 earnings after the market closed on Thursday. The drug delivery company, which is a leader in tubeless insulin pump technology with its OmniPod System, posted revenue growth that exceeded its...
PODD: 32.11 (+0.97), AMGN: 161.10 (+4.51)
Insulet Reaffirms Second Quarter and Full Year 2016 Guidance
PR Newswire - Tue May 03, 1:35PM CDT
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System (OmniPod System), today reaffirmed its second quarter and full year 2016 guidance. A recent preferred provider communication by UnitedHealthcare regarding in-network DME insulin pumps is not expected to have a material impact on OmniPod System coverage nor on Insulet's financial results.
PODD: 32.11 (+0.97)
Insulet reports 1Q loss
Automated Insights - Thu Apr 28, 3:55PM CDT
BILLERICA, Mass. (AP) _ Insulet Corp. (PODD) on Thursday reported a loss of $12.5 million in its first quarter.
PODD: 32.11 (+0.97)
Insulet Reports First Quarter 2016 Financial Results
PR Newswire - Thu Apr 28, 3:01PM CDT
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System (OmniPod System), today announced financial results for the three months ended March 31, 2016.
PODD: 32.11 (+0.97)
Insulet Up 21.4% Since SmarTrend Uptrend Call (PODD)
Comtex SmarTrend(R) - Tue Apr 26, 1:43PM CDT
SmarTrend identified an Uptrend for Insulet (NASDAQ ODD) on February 24th, 2016 at $28.56. In approximately 2 months, Insulet has returned 21.43% as of today's recent price of $34.68.
PODD: 32.11 (+0.97)
16.9% Return Seen to Date on SmarTrend Insulet Call (PODD)
Comtex SmarTrend(R) - Tue Apr 05, 1:25PM CDT
SmarTrend identified an Uptrend for Insulet (NASDAQ ODD) on February 24th, 2016 at $28.56. In approximately 1 month, Insulet has returned 16.95% as of today's recent price of $33.40.
PODD: 32.11 (+0.97)
Insulet Corporation to Announce First Quarter 2016 Financial Results on April 28, 2016
PR Newswire - Wed Mar 30, 3:05PM CDT
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced plans to release its financial results for the first quarter of 2016 on April 28, 2016 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).
PODD: 32.11 (+0.97)
Global Insulin Pump Market with Focus on Patch Pumps 2016-2020 - Key Players are Animas Corporation, Cellnovo, Insulet Corporation, Medtronic & Roche - Research and Markets
BusinessWire - Thu Mar 10, 8:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vmqmv/global_insulin) has announced the addition of the "Global Insulin Pump Market with Focus on Patch Pumps 2016-2020" report to their offering.
PODD: 32.11 (+0.97), MDT: 88.36 (+0.87)
Insulet Announces Organizational Enhancements
PR Newswire - Wed Mar 02, 3:05PM CST
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System (OmniPod System), today announced the promotion of Shacey Petrovic to the newly-created role of President, Insulet Diabetes Products and the recent appointment of Charles Alpuche as Senior Vice President of Global Manufacturing and Operations.
PODD: 32.11 (+0.97)
Notable Thursday Option Activity: PODD, ASPS, CNL
DividendChannel.com - Thu Feb 25, 2:30PM CST
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Insulet Corp , where a total volume of 4,566 contracts has been traded thus far today, a contract volume which is representative of...
PODD: 32.11 (+0.97)
Insulet elects David A. Lemoine to board
M2 - Wed Feb 10, 5:27AM CST
Insulin pump company Insulet Corporation (NasdaqGS ODD) revealed on Tuesday that it has appointed David A. Lemoine to its board of directors.
PODD: 32.11 (+0.97)
Insulet Appoints David A. Lemoine to Board of Directors
PR Newswire - Tue Feb 09, 3:05PM CST
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced that David A. Lemoine has been appointed to Insulet's Board of Directors. With his appointment, the Board is now comprised of nine directors, eight of whom are independent.
PODD: 32.11 (+0.97)
Health insurer's limit on insulin pumps worries patients
By TOM MURPHY - AP - Fri Jun 24, 10:18AM CDT
Stephanie Rodenberg-Lewis wasn't happy with her insulin pump and finally switched two years ago to another brand. Now her health insurer is pushing her to go back.
PODD: 32.11 (+0.97), UNH: 141.27 (+0.47), AET: 117.00 (+1.53)
What Investors are Making of These Healthcare Stocks? - Antares Pharma, Globus Medical, NuVasive, and Insulet
PR Newswire - Fri Jun 24, 6:49AM CDT
Since the financial crisis, the Healthcare sector has proven to be defensive against market downturns, continuing to present opportunities for growth. Today's featured companies on Stock-Callers.com belong in this arena: Antares Pharma Inc. (NASDAQ: ATRS), Globus Medical Inc. (NYSE: GMED), NuVasive Inc. (NASDAQ: NUVA), and Insulet Corp. (NASDAQ: PODD). Learn more about these stocks and receive your complimentary trade alerts at:
PODD: 32.11 (+0.97), GMED: 24.87 (+0.42), NUVA: 60.82 (+1.11), ATRS: 1.03 (+0.02)
First Week of PODD August 19th Options Trading
DividendChannel.com - Tue Jun 21, 9:49AM CDT
Investors in Insulet Corp saw new options begin trading this week, for the August 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PODD options chain for the new August 19th contracts and identified one...
PODD: 32.11 (+0.97)
Insulet Partners with Joslin Diabetes Center to Implement a Unique Training Certification for Insulet's Clinical Team
BusinessWire - Fri Jun 10, 5:00AM CDT
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod(R) Insulin Management System, today announced that almost 100 members of Insulet's North American clinical team have completed a customized certification program designed and led by the Joslin Diabetes Center for Insulet. The Advanced Diabetes Educator in Pump Therapy (ADEPT(TM)) certification provides Insulet's clinical team with customized, advanced training to deliver enhanced support for individuals who are managing their diabetes using continuous subcutaneous insulin infusion therapy. The Company's partnership with Joslin will enable Insulet's clinical team to provide unparalleled training and support for healthcare practitioners and their Omnipod patients.
PODD: 32.11 (+0.97)
Insulet to Present Omnipod(R) Clinical Studies on Type 1 and Type 2 Diabetes During the American Diabetes Association's 76th Scientific Sessions
BusinessWire - Wed Jun 08, 5:38PM CDT
--Dr. Frank Doyle to Share Exciting New Data on the Insulet-Licensed Artificial Pancreas Algorithm
PODD: 32.11 (+0.97)
Insulet Rises 2.31% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon May 23, 4:28PM CDT
Insulet (NASDAQ
ODD) traded in a range yesterday that spanned from a low of $28.33 to a high of $29.42. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $28.86 on volume of 332,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. PODD: 32.11 (+0.97)
Insulet Launches New Omnipod(R) Podder(TM) Community Platform
BusinessWire - Mon May 23, 5:00AM CDT
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod(R) Insulin Management System (Omnipod System), today announced the launch of a new online user community platform. This new platform will increase patient engagement and awareness of Omnipod by empowering Omnipod customers to share their experiences and insights and provide support to the large and growing Podder(TM) community. The launch of the Podders community platform coincides with Insulet's exciting new patient mobile app and branding, as well as the Company's debut on social media via Facebook (myomnipod) and Twitter (@myomnipod).
PODD: 32.11 (+0.97)
Why Insulet Corporation and Tandem Diabetes Care Both Tanked Today
Brian Feroldi, The Motley Fool - Motley Fool - Tue May 03, 3:50PM CDT
PHOTO CREDIT: INSULET. What: Shares of Insulet Corporation and Tandem Diabetes Care , both medical-device companies primarily focused on creating products that help treat diabetes, plunged by double digits today after Tandem released some...
PODD: 32.11 (+0.97), TNDM: 7.71 (+0.26)
Insulet Pumps Out 69% Revenue Growth in Q1, Reaffirms 2016 Guidance
Beth McKenna, The Motley Fool - Motley Fool - Tue May 03, 2:04PM CDT
Insulet reported its first-quarter 2016 earnings after the market closed on Thursday. The drug delivery company, which is a leader in tubeless insulin pump technology with its OmniPod System, posted revenue growth that exceeded its...
PODD: 32.11 (+0.97), AMGN: 161.10 (+4.51)
Insulet Reaffirms Second Quarter and Full Year 2016 Guidance
PR Newswire - Tue May 03, 1:35PM CDT
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System (OmniPod System), today reaffirmed its second quarter and full year 2016 guidance. A recent preferred provider communication by UnitedHealthcare regarding in-network DME insulin pumps is not expected to have a material impact on OmniPod System coverage nor on Insulet's financial results.
PODD: 32.11 (+0.97)
Insulet reports 1Q loss
Automated Insights - Thu Apr 28, 3:55PM CDT
BILLERICA, Mass. (AP) _ Insulet Corp. (PODD) on Thursday reported a loss of $12.5 million in its first quarter.
PODD: 32.11 (+0.97)
Insulet Reports First Quarter 2016 Financial Results
PR Newswire - Thu Apr 28, 3:01PM CDT
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System (OmniPod System), today announced financial results for the three months ended March 31, 2016.
PODD: 32.11 (+0.97)
Insulet Up 21.4% Since SmarTrend Uptrend Call (PODD)
Comtex SmarTrend(R) - Tue Apr 26, 1:43PM CDT
SmarTrend identified an Uptrend for Insulet (NASDAQ
ODD) on February 24th, 2016 at $28.56. In approximately 2 months, Insulet has returned 21.43% as of today's recent price of $34.68. PODD: 32.11 (+0.97)
16.9% Return Seen to Date on SmarTrend Insulet Call (PODD)
Comtex SmarTrend(R) - Tue Apr 05, 1:25PM CDT
SmarTrend identified an Uptrend for Insulet (NASDAQ
ODD) on February 24th, 2016 at $28.56. In approximately 1 month, Insulet has returned 16.95% as of today's recent price of $33.40. PODD: 32.11 (+0.97)
Insulet Corporation to Announce First Quarter 2016 Financial Results on April 28, 2016
PR Newswire - Wed Mar 30, 3:05PM CDT
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced plans to release its financial results for the first quarter of 2016 on April 28, 2016 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).
PODD: 32.11 (+0.97)
Global Insulin Pump Market with Focus on Patch Pumps 2016-2020 - Key Players are Animas Corporation, Cellnovo, Insulet Corporation, Medtronic & Roche - Research and Markets
BusinessWire - Thu Mar 10, 8:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vmqmv/global_insulin) has announced the addition of the "Global Insulin Pump Market with Focus on Patch Pumps 2016-2020" report to their offering.
PODD: 32.11 (+0.97), MDT: 88.36 (+0.87)
Insulet Announces Organizational Enhancements
PR Newswire - Wed Mar 02, 3:05PM CST
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System (OmniPod System), today announced the promotion of Shacey Petrovic to the newly-created role of President, Insulet Diabetes Products and the recent appointment of Charles Alpuche as Senior Vice President of Global Manufacturing and Operations.
PODD: 32.11 (+0.97)
Notable Thursday Option Activity: PODD, ASPS, CNL
DividendChannel.com - Thu Feb 25, 2:30PM CST
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Insulet Corp , where a total volume of 4,566 contracts has been traded thus far today, a contract volume which is representative of...
PODD: 32.11 (+0.97)
Insulet elects David A. Lemoine to board
M2 - Wed Feb 10, 5:27AM CST
Insulin pump company Insulet Corporation (NasdaqGS
ODD) revealed on Tuesday that it has appointed David A. Lemoine to its board of directors. PODD: 32.11 (+0.97)
Insulet Appoints David A. Lemoine to Board of Directors
PR Newswire - Tue Feb 09, 3:05PM CST
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced that David A. Lemoine has been appointed to Insulet's Board of Directors. With his appointment, the Board is now comprised of nine directors, eight of whom are independent.
PODD: 32.11 (+0.97)
